Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10096-021-04203-8 http://scihub22266oqcxt.onion/10.1007/s10096-021-04203-8 33660134!7928199!33660134     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Microbiol+Infect+Dis 2021 ; 40 (6): 1309-1317 Nephropedia Template TP {{tp|p=33660134|t=2021. Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies |pdf=|usr=}}{{33660134}} gab.com Text Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies JO: Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33660134 #FOAvip ELISA and chemiluminescence serological assays for COVID-19 are currently incorporating only one or two SARS-CoV-2 antigens. We developed an automated Western immunoblotting as a complementary serologic assay for COVID-19. The Jess(TM) Simple Western system, an automated capillary-based assay, was used, incorporating an inactivated SARS-CoV-2 lineage 20a strain as the source of antigen, and total immunoglobulins (IgG, IgM, IgA) detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from coronavirus-negative control sera. We also compared this assay with the EUROIMMUN(R) SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity was further detected in 9/76 (14%) samples collected from patients diagnosed with seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the subset of sera collected more than 2 weeks after the onset of symptoms, the sensitivity was 94% and the specificity 93%, the latter value probably reflecting cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western immunoblotting presented a substantial agreement (90%) with the compared ELISA (Cohen's Kappa=0.64). Automated Western immunoblotting may be used as a second line test to monitor exposure of people to HCoVs including SARS-CoV-2. Twit Text FOAVip Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies ????Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33660134 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33660134 #FOAvip English Wikipedia <ref>{{Cite pmid|33660134}}</ref> Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies #MMPMID33660134 Edouard S; Jaafar R; Orain N; Parola P; Colson P; La Scola B; Fournier PE; Raoult D; Drancourt M Eur J Clin Microbiol Infect Dis 2021[Jun]; 40 (6): 1309-1317 PMID33660134show ga ELISA and chemiluminescence serological assays for COVID-19 are currently incorporating only one or two SARS-CoV-2 antigens. We developed an automated Western immunoblotting as a complementary serologic assay for COVID-19. The Jess(TM) Simple Western system, an automated capillary-based assay, was used, incorporating an inactivated SARS-CoV-2 lineage 20a strain as the source of antigen, and total immunoglobulins (IgG, IgM, IgA) detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from coronavirus-negative control sera. We also compared this assay with the EUROIMMUN(R) SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity was further detected in 9/76 (14%) samples collected from patients diagnosed with seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the subset of sera collected more than 2 weeks after the onset of symptoms, the sensitivity was 94% and the specificity 93%, the latter value probably reflecting cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western immunoblotting presented a substantial agreement (90%) with the compared ELISA (Cohen's Kappa=0.64). Automated Western immunoblotting may be used as a second line test to monitor exposure of people to HCoVs including SARS-CoV-2. |*Blotting, Western[MESH] |Antibodies, Viral/blood/*isolation & purification[MESH] |Automation, Laboratory[MESH] |COVID-19/*diagnosis[MESH] |Coronavirus Nucleocapsid Proteins/immunology[MESH] |Cross Reactions[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Humans[MESH] |Phosphoproteins/immunology[MESH] |SARS-CoV-2/immunology[MESH] |Sensitivity and Specificity[MESH]Automated Western immunoblotting detection of anti-SARS-CoV-2 serum an(epmc).pdf DeepDyve Pubget Overpricing